

April 28, 2023

To the press and whom it may concern,

Company name: CMIC HOLDINGS Co., Ltd.
 Representative: Kazuo Nakamura, Representative Director and CEO
 (TSE Prime Code No. 2309)
 Inquiries: Wataru Mochizuki, Corporate Director and CFO
 (Phone: +81-3-6779-8000)

Notice of Revision of Full-Year Earnings Forecast

CMIC HOLDINGS Co., Ltd. (the "Company") hereby announces the following revisions to the forecasts of the full-year consolidated results announced on November 8, 2022 for the fiscal year ending September 30, 2023.

Notes

1. Revision of FY2023 Full-year Forecast (October 1, 2022 to September 30, 2023)

	Net sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	95,000	5,000	4,700	2,900	165.23
Current revised forecast (B)	105,000	10,300	9,000	7,300	420.42
Increase (B-A)	10,000	5,300	4,300	4,400	-
Rate of change (%)	10.5	106.0	91.5	151.7	-
(Reference) Results for the previous fiscal year (FY2022)	108,461	11,845	13,450	8,387	469.44

(Reasons for amendment)

Taking into account the results of the first half of the current fiscal year, the forecast for the fiscal year ending September 30, 2023 incorporates the forecast for matters affecting the first half of the fiscal year based on information available at this time.

In the second quarter consolidated cumulative period, we substantially exceeded our initial forecast due to a significant increase in municipal support services related to COVID-19 and a gain on sale of investment securities of ¥ 3,349 million recorded as an extraordinary income.

As for matters that will affect business results in the second half of the fiscal year, as announced in the "Notice of Change of CDMO Business Subsidiary and Notice of Strategic Business Alliance with Dai Nippon Printing Co., Ltd." dated April 17, 2023, some subsidiaries in the CDMO (Contract Development and Manufacturing Organization) business of our Pharmaceuticals Solutions are expected to become equity-method affiliates from June 2023.

As for the impact of COVID-19, the shift of the classification of COVID-19 to category 5 under the Infectious Diseases Control Law effective May 8, 2023 is expected to reduce the number of vaccination projects that have driven our performance in the first half of the current fiscal year.

Further, the situation in Ukraine will not have a significant direct impact on our operations in Russia and Ukraine, as we do not have any offices in either country, but there will be an impact on our profits due to higher energy and logistics costs, which we have incorporated into our forecast.

Based on the above, we have revised upward our full-year forecasts for the fiscal year ending September 30, 2023, to net sales of ¥ 105,000 million, operating profit of ¥ 10,300 million, ordinary profit of ¥ 9,000 million, and profit attributable to owners of parent of ¥7,300 million, respectively.